keyword
MENU ▼
Read by QxMD icon Read
search

Omalizumab

keyword
https://www.readbyqxmd.com/read/28183482/use-of-biological-agents-in-asthma-pharmacoeconomic-lessons-learned-from-omalizumab
#1
EDITORIAL
Steven Draikiwicz, John Oppenheimer
No abstract text is available yet for this article.
February 2017: Chest
https://www.readbyqxmd.com/read/28181317/ace-inhibitors-may-interfere-with-omalizumab-in-chronic-spontaneous-urticaria
#2
Riccardo Asero
The extrinsic pathway of coagulation cascade is activated in chronic spontaneous urticaria (CSU), and such activation parallels disease severity (1). D-dimer levels are elevated in cases resistant to antihistamines (2) and/or cyclosporine (3). Omalizumab is highly effective in most patients with severe, antihistamine-resistant CSU. Two cases of severe CSU in which ACE-inhibitor was associated with the loss of response to omalizumab are reported. This article is protected by copyright. All rights reserved.
February 9, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28168968/refractory-solar-urticaria-successfully-treated-with-omalizumab-with-normalization-of-phototest
#3
A Combalia, C Fernández-Sartorio, P Aguilera
No abstract text is available yet for this article.
February 3, 2017: Actas Dermo-sifiliográficas
https://www.readbyqxmd.com/read/28141955/investigational-new-drugs-for-allergic-rhinitis
#4
Peter A Ricketti, Sultan Alandijani, Chen Hsing Lin, Thomas B Casale
Allergic rhinitis (AR) is a multifactorial disease characterized by paroxysmal symptoms of sneezing, rhinorrhea, postnasal drip and nasal congestion. For over a century, subcutaneous allergen immunotherapy (SCIT) has been recognized as the most effective therapy to date that may modify the underlying disease course and provide long-term benefits for individuals refractory to pharmacotherapy. However, over the past 25 years, there has been substantial growth in developing alternative therapies to traditional SCIT...
January 31, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28137490/comparative-effectiveness-of-mepolizumab-and-omalizumab-in-severe-asthma-an-indirect-treatment-comparison
#5
Sarah M Cockle, Gillian Stynes, Necdet B Gunsoy, Daniel Parks, Rafael Alfonso-Cristancho, Jaro Wex, Eric S Bradford, Frank C Albers, Jenny Willson
BACKGROUND: Severe asthma is a heterogeneous disease. Patients with both eosinophilic and allergic asthma phenotypes may be eligible for treatment with mepolizumab and omalizumab. Evidence on the relative effectiveness of these treatments in this 'overlap' population would be informative for clinical and payer decision making. METHODS: A systematic literature review and indirect treatment comparison (Bayesian framework) were performed to assess the comparative effectiveness and tolerability of mepolizumab and omalizumab, as add-ons to standard of care...
February 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28137489/severe-and-non-severe-asthma-in-the-community-a-large-electronic-database-analysis
#6
Shabtai Varsano, David Segev, David Shitrit
BACKGROUND: A large electronic database analysis was conducted in a community of 351,799 people, ages 20-70 years to determine the prevalence and clinical characteristics of severe asthma, according to 2014 international guidelines and healthcare utilization. METHODS: Severe asthmatics were grouped into controlled severe-asthma and uncontrolled severe-asthma and additional subgroups of uncontrolled severe asthma on the basis of medications dispensed. Non-asthmatic population at the same ages served as controls...
February 2017: Respiratory Medicine
https://www.readbyqxmd.com/read/28137226/management-of-status-asthmaticus-in-children
#7
Kam-Lun E Hon, Alexander K C Leung
BACKGROUND: Status asthmaticus is an acute exacerbation of asthma that is persistent and intractable and remains unresponsive to initial treatment with bronchodilators and systemic corticosteroids and that can result in hypoxemia, hypercarbia, and secondary respiratory failure. METHOD: We reviewed treatment and recent patents on management of status asthmaticus. CONCLUSIONS: Supplemental oxygen should be given to maintain an oxygen saturation of ≥92% in room air...
30, 2017: Recent Patents on Inflammation & Allergy Drug Discovery
https://www.readbyqxmd.com/read/28125304/omalizumab-for-treating-chronic-spontaneous-urticaria-an-expert-review-on-efficacy-and-safety
#8
Ana M Giménez-Arnau
Chronic spontaneous urticaria (CSU) is characterized by the recurrence of itchy hives and/or angioedema for greater than six weeks, with no known external trigger. Omalizumab, a humanized, recombinant, monoclonal anti-IgE antibody, is the only approved add-on therapy for H1-antihistamine refractory CSU patients. Areas covered: The objective of this article is to discuss the mechanism of action, pharmacokinetics and pharmacodynamics of omalizumab for the treatment of CSU. The review also summarizes efficacy and safety data from proof-of-concept, Phase II (X-QUISITE, MYSTIQUE), and pivotal Phase III omalizumab studies (ASTERIA I, ASTERIA II, and GLACIAL)...
January 26, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28117272/aspirin-tolerance-in-patients-with-nonsteroidal-anti-inflammatory-drug-exacerbated-respiratory-disease-following-treatment-with-omalizumab
#9
Elsa Phillips-Angles, Pilar Barranco, Magdalena Lluch-Bernal, Javier Dominguez-Ortega, Valentín López-Carrasco, Santiago Quirce
No abstract text is available yet for this article.
January 20, 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28108337/cardiovascular-and-cerebrovascular-events-among-patients-receiving-omalizumab-pooled-analysis-of-patient-level-data-from-25-randomized-double-blind-placebo-controlled-clinical-trials
#10
Carlos Iribarren, Kenneth J Rothman, Mary S Bradley, Gillis Carrigan, Mark D Eisner, Hubert Chen
Among patients who participated in randomized clinical trials of omalizumab, no substantial overall increase in the risk of cardiovascular events was observed in the treatment arms compared with placebo. <29/35 words>.
January 17, 2017: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28101900/bronchial-thermoplasty-in-severe-asthma-in-australia
#11
David Langton, Joy Sha, Alvin Ing, David Fielding, Erica Wood
BACKGROUND: Bronchial thermoplasty is an approved bronchoscopic intervention for the treatment of severe asthma. However, limited published experience exists outside of clinical trials regarding patient selection and outcomes achieved. Aims To evaluate the effectiveness and safety of bronchial thermoplasty in patients with severe asthma encountered in clinical practice. METHODS: This is a retrospective analysis of the first 'real world' data from Australia. The following outcomes were measured prior to, and 6 months following bronchial thermoplasty: Spirometry, Asthma Control Questionnaire-5 (ACQ-5) score, reliever and preventer medication use, and exacerbation history...
January 19, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28094120/omalizumab-associated-eosinophilic-granulomatosis-with-polyangiitis-churg-strauss-syndrome
#12
Salik Nazir, Niranjan Tachamo, Shoaib Bilal Fareedy, Muhammad Sohail Khan, Saroj Lohani
No abstract text is available yet for this article.
January 13, 2017: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28089687/stabilizing-effects-for-antibody-formulations-and-safety-profiles-of-cyclodextrin-polypseudorotaxane-hydrogels
#13
Taishi Higashi, Naoko Ohshita, Tatsunori Hirotsu, Yoshihito Yamashita, Keiichi Motoyama, Sawako Koyama, Ruriko Iibuchi, Takayuki Uchida, Shiuhei Mieda, Kenji Handa, Tomoaki Kimoto, Hidetoshi Arima
Antibodies often have poor physicochemical stability during storage and/or transport, which is a serious drawback for the development of antibody-based drugs. In this study, we prepared polypseudorotaxane (PPRX) hydrogels consisting of cyclodextrins (CyDs) and polyethylene glycol (PEG), and evaluated them as stabilizers for commercially available antibody-based drugs. α-CyD and γ-CyD formed PPRX hydrogels with PEG (MW 20,000 Da) in the presence of antibody-based drugs such as omalizumab, palivizumab, panitumumab, and ranibizumab...
January 12, 2017: Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28078079/looking-forward-to-new-targeted-treatments-for-chronic-spontaneous-urticaria
#14
REVIEW
Emek Kocatürk, Marcus Maurer, Martin Metz, Clive Grattan
The introduction of omalizumab to the management of chronic spontaneous urticaria (CSU) has markedly improved the therapeutic possibilities for both, patients and physicians dealing with this disabling disease. But there is still a hard core of patients who do not tolerate or benefit from existing therapies and who require effective treatment. Novel approaches include the use of currently available drugs off-licence, investigational drugs currently undergoing clinical trials and exploring the potential for therapies directed at pathophysiological targets in CSU...
2017: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/28051241/effects-of-omalizumab-therapy-on-allergic-rhinitis-a-pilot-study
#15
S Masieri, C Cavaliere, E Begvarfaj, D Rosati, A Minni
OBJECTIVE: The use of omalizumab, a humanized monoclonal antibody able to binding Ig-E, is currently authorized only for treatment of severe bronchial asthma. The use of omalizumab in other Ig-E related diseases is off-label, although some studies have provided promising results about it. The aim of this study was to evaluate if therapy with omalizumab in patients affected by asthma and allergic rhinitis has an impact also on allergic rhinitis-related symptoms. PATIENTS AND METHODS: A longitudinal study was conducted on 11 patients affected by severe asthma and a periodic allergic rhinitis...
December 2016: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28042528/desensitization-for-peanut-allergies-in-children
#16
Rekha D Jhamnani, Pamela Frischmeyer-Guerrerio
Immunotherapy for peanut allergy has been an exploding topic of study within the last few years. Sublingual, epicutaneous, and oral immunotherapy are being investigated and show promise in the treatment of peanut allergy. Oral immunotherapy has shown the most clinical benefit; however, sublingual and epicutaneous immunotherapy appear to have the most favorable safety profiles. Most studies to date suggest that only a minority of subjects achieve sustained unresponsiveness to peanut after discontinuation of immunotherapy...
September 2016: Current Treatment Options in Allergy
https://www.readbyqxmd.com/read/28029407/management-of-chronic-spontaneous-urticaria-in-routine-clinical-practice-a-delphi-method-questionnaire-among-specialists-to-test-agreement-with-current-european-guidelines-statements
#17
A Giménez-Arnau, M Ferrer, J Bartra, I Jáuregui, M Labrador-Horrillo, J Ortiz de Frutos, J F Silvestre, J Sastre, M Velasco, A Valero
BACKGROUND: Chronic spontaneous urticaria (CSU) is a frequent clinical entity that often presents a diagnostic and therapeutic challenge. OBJECTIVE: To explore the degree of agreement that exists among the experts caring for patients with CSU diagnosis, evaluation, and management. METHODS: An online survey was conducted to explore the opinions of experts in CSU, address controversial issues, and provide recommendations regarding its definition, natural history, diagnosis, and treatment...
October 28, 2016: Allergologia et Immunopathologia
https://www.readbyqxmd.com/read/28017628/eosinophilic-esophagitis-during-peanut-oral-immunotherapy-with-omalizumab
#18
Caitlin M Burk, Evan S Dellon, Pamela H Steele, Yamini V Virkud, Mike Kulis, A Wesley Burks, Brian P Vickery
No abstract text is available yet for this article.
December 22, 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/27995273/-partial-response-of-solar-urticaria-to-omalizumab-therapy
#19
L Kowalzick, W Thiel, C Bielfeld, H Ziegler, L Eickenscheidt
The treatment of solar urticaria is regarded as difficult. In some cases good responses to the anti-IgE antibody omalizumab (Xolair®), approved for treatment of chronic spontaneous urticaria, have been reported. We report on a 50-year-old Caucasian woman who for the last 5 years has developed localized itching and stinging erythemas following exposure to sunlight accompanied sometimes by anaphylactic reactions. Oral antihistamines in three- to four-fold doses and a topical sun screen had been only partially effective in long-term use...
December 19, 2016: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/27993289/beneficial-effects-of-omalizumab-therapy-in-allergic-bronchopulmonary-aspergillosis-a-synthesis-review-of-published-literature
#20
REVIEW
Jian-Xiong Li, Li-Chao Fan, Man-Hui Li, Wei-Jun Cao, Jin-Fu Xu
Omalizumab, a humanized mAb that binds to IgE, has been an effective therapy for patients with severe allergic asthma; however, there are few clinical trials examining the efficacy of Omalizumab in patients with allergic bronchopulmonary aspergillosis (ABPA) except some case reports. To assess the clinical and immunological effects of Omalizumab in ABPA patients, we made a synthesis review of 102 cases from 30 published literature, analyzed the effects of Omalizumab therapy in ABPA and conducted subgroup analyses to determine factors that influenced the therapy endpoints...
January 2017: Respiratory Medicine
keyword
keyword
7812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"